Table 2:
Base editor | Construction (N to C) | PAM | Editing window |
Efficiency | References |
---|---|---|---|---|---|
SaBE3 | rAPOCBEC1-SaCas9n-UGI | NNGRRT (R=G or A) |
N9 to N15 | ~50% | Y. B. Kim et al., 2017 |
CBE4 | rAPOCBEC1-Cas9n-UGI-UGI | NGG | N13 to N17 | ~50% | Komor et al., 2017 |
SaBE4-Gam | Gam-rAPOCBEC1-SaCas9n-UGI-UGI | NNGRRT | N9 to N15 | ~50% | Komor et al., 2017 |
HF2-BE2 | APOCBEC1-HF2-dCas9-UGI | NGG | N/A | 100% | Liang, Sun, et al., 2017 |
BE-PLUS | nCas9-GCN4, scFv-APOBEC-UGI | NGG | N5 to N17 | 42.2% | Jiang et al., 2018 |
dCpf1-BEs | +/−NLS, rAPOCBEC1-YE-dCpf1-UGI, +/−3xFree UGI | TTTV | N8 to N13 | ~10–31% | Li et al., 2018 |
TAM | dcas9-AID (AIDx), +/−UGI | NGG | N12 to N16 | 52% | Ma et al., 2016 |
CRISPR-X | dCas9-directed MS2–AID*Δ | NGG | N50 to -N50 | > 20% | Hess et al., 2016 |
Target-AID | dCas9-PmCDA1-UGI/Cas9n-PmCDA1-UGI | NG | N15 to N19 | 15%−55% | Nishida et al., 2016 |
TALE-AID ZFN-AID |
TALE-AID ZFN-AID |
N/A | N/A | 2.5% | Luhan Yang et al., 2016 |
ABE7.10 | TadA-TadA(7.10)*–XTEN–Cas9n–NLS | NGG | N13 to N17 | 58%±4.0% | Gaudelli et al., 2017 |
xABE | TadA-TadA(7.10)*–XTEN–xCas9–NLS | NG, GAA, and GAT | N13 to N17 | N/A | Hu et al., 2018 |
SaABE | TadA-TadA(7.10)*–XTEN–SaCas9n–NLS | NNGRRT | N9 to N15 | N/A | Hua, Tao, & Zhu, 2019 |
VQR-ABE | TadA-TadA(7.10)*–XTEN–VQR-Cas9n–NLS | NGA | N13 to N17 | N/A |
Hua, Tao, & Zhu, 2019 L. Yang et al., 2018 |
VRER-ABE | TadA-TadA(7.10)*–XTEN–VRER-Cas9n–NLS | NGCG | N13 to N17 | N/A | Hua, Tao, & Zhu, 2019 |
Sa(KKH)- ABE |
TadA-TadA(7.10)*–XTEN–Sa(KKH)- ABE -Cas9n–NLS |
NNNRRT | N9 to N15 | N/A |
Hua, Tao, & Zhu, 2019 L. Yang et al., 2018 |